Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Post by gebremeskelon Jul 15, 2024 1:43pm
297 Views
Post# 36133283

Cristiano Franzi now SVP International at Solventum

Cristiano Franzi now SVP International at SolventumSolventum was created 3 1/2 months ago as a spin off of 3M's health care business. It had sales of $8.2 B in 2023 as part of 3M and has 22,000 employees.

SPECTRAL MEDICAL'S
BOARD OF DIRECTORS
 
Cristiano Franzi
Director
 
Mr. Franzi is a seasoned global healthcare executive and board director with a 30-year track record at leading global Med-Tech companies. As Regional President for businesses of up to $4 billion in size at Solventum, Baxter, Medtronic, and Covidien, Mr. Franzi has proven his ability to deliver value by developing compelling visions, identifying new market opportunities, and articulating clear growth strategies while streamlining operations and implementing highly disciplined business models.
 
Mr. Franzi currently serves as SVP International at Solventum, which in April 2024 spun from 3M. From 2017 to 2023, Mr. Franzi served as President of Baxter EMEA, where he also served as the interim global lead for the spin-off of the $4.5 billion Renal Care business (“Vantive”). Prior to Baxter, Mr. Franzi served as President, EMEA at Medtronic, and prior to that as President, EMEA at Covidien. Before that, he covered roles of increasing responsibilities at ev3, a private equity-backed medical device start up, where he played a key role in the international expansion of the company from inception to its $156 million IPO in 2005.
 
He has overseen large acquisitions, mergers, integrations, and divestitures: he worked with Baxter’s Board on the strategy, due diligence, and integration for the $10.5 billion Hillrom acquisition and the preparations for the spin-off of the Renal Care business; he co-led the integration of Covidien at Medtronic in EMEA following the $42.9 billion acquisition.
 
Additionally, he has served as an industry leader on the Board of MedTech Europe, the industry association in Europe. Mr. Franzi also serves as an expert advisor to leading global private equity firms and is an angel investor in MedTech startups. Mr. Franzi completed the Advanced Management Program (AMP197) at Harvard Business School, holds an MBA from George Washington University, and a bachelor’s degree in business administration from The American University.
<< Previous
Bullboard Posts
Next >>